Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: August 30, 2021
Expiration Date: August 30, 2022

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Bruton’s tyrosine kinase inhibitor (BTKi) therapy has emerged as a major treatment option for patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL) and other B-cell malignancies that can improve quality of life for patients. To ensure optimal patient outcomes, however, it is essential to maintain ongoing therapy. This requires prompt recognition and management of the unique adverse events (AEs) associated with BTKi therapy. However, data suggest that management of BTKi AEs by health care professionals (HCPs) often diverges from evidence-based expert recommendations, especially grade 3/4 AEs. In this activity, Dr. Vose, Dr. Stone, Dr. Lamanna, and Dr. Campbell discuss the treatment for CLL and MCL and challenges you’re likely to face in your practice this year.

This activity was previously presented as a live webinar. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with CLL/SLL and MCL.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Select a BTKi therapy for patients with CLL/SLL and MCL, considering safety data and associated patient selection factors
  • Employ AE monitoring and management strategies for individual patients with CLL and MCL on BTKi therapies
  • Collaborate with the multidisciplinary team, such as hematology/oncology, cardiology, and rheumatology clinicians to effectively support AE monitoring and management strategies

Agenda

Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL – Julie M. Vose, MD, MB; Jeremy R. Stone, MD; Nicole Lamanna, MD; Peter Campbell, PharmD, BCOP

Instructions for Participation and Credit

This activity is eligible for credit through August 30, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology/Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Dr. Julie Vose received her medical degree from the University of Nebraska Medical Center (UNMC) where she also completed her residency in internal medicine, served as chief resident, and completed a fellowship in hematology/oncology. In addition, she completed an MBA in health administration through the University of Colorado Business School in Denver. She is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at UNMC in Omaha.

Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as monoclonal antibodies, vaccine and cellular therapies, pathway-directed agents, and stem cell transplantation. She has published extensively on improvements in therapy and transplantation research which have added substantially to the research and knowledge base for the therapy of lymphoma. She was 2015/2016 president for the American Society of Clinical Oncology (ASCO).

Jeremy R. Stone, MD
Assistant Professor of Cardiovascular Medicine
University of Nebraska Medical Center 
Omaha, Nebraska

Dr. Jeremy Stone received his medical degree from the University of Nebraska Medical Center (UNMC), where he also completed his internal medicine residency. He then completed a fellowship in cardiovascular disease from the University of Chicago. Dr. Stone is an  Assistant Professor of Cardiovascular Medicine at UNMC where his career focus is on cardio-oncology, cardiac imaging, and consultative cardiology.

Dr. Stone is board certified by the Certification Board of Cardiovascular Magnetic Resonance (CBCMR), the American Board of Internal Medicine (cardiovascular disease and internal medicine), the National Board of Echocardiography (NBE), the Certification Board of Nuclear Cardiology (CBNC), and by the Registered Physician in Vascular Interpretation (RPVI). He holds memberships in the American College of Physicians, American College of Cardiology, American Society of Echocardiography, Society for Cardiac Magnetic Resonance, and the Internal Society of Cardio-Oncology.

Nicole Lamanna, MD
Associate Professor of Medicine
Director
Chronic Lymphocytic Leukemia Program
Columbia University Medical Center
New York, New York

Dr. Nicole Lamanna received her medical degree from Albert Einstein College of Medicine in the Bronx. She was a medical intern, resident, and chief resident in Department of Medicine at NYU, and was a chief fellow and hematology/oncology fellow in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Lamanna is an Associate Professor of Medicine and Director of the Chronic Lymphocytic Leukemia Program on the Leukemia Service for the Hematologic Malignancies Section in the Hematology/Oncology Division at Columbia University Medical Center in New York City.

Dr. Lamanna specializes in the treatment of adult patients with acute and chronic leukemias. Her area of clinical expertise is in treatment of patients with lymphoid leukemias, specifically chronic lymphocytic leukemia (CLL). Her clinical research focus has been the development of novel combination therapies that include chemo-immunotherapy, immune-modulatory drugs, kinase inhibitors, bcl-2 inhibitors, and monoclonal antibodies. Her research aims to have also encompassed the development of safer and more effective therapies for older patients with CLL and the investigation of novel agents for all patients with this disease. Dr. Lamanna has lectured at international and national meetings and has published in various scientific journals, including Blood, Journal of Clinical Oncology, and the New England Journal of Medicine.

Peter Campbell, PharmD, BCOP
Clinical Pharmacy Manager
Hematology/Oncology
Program Director
Post-Graduate Year Two Oncology Pharmacy Residency
New York-Presbyterian Hospital
New York, New York

Dr. Peter Campbell  received his doctor of pharmacy degree at St John’s University, College of Pharmacy and Health Sciences in Queens, New York. He completed his post graduate pharmacy residencies at New York-Presbyterian Hospital. Dr. Campbell is a clinical pharmacist specializing in adult leukemia. He is the Clinical Pharmacy Manager of Hematology/Oncology, and Program Director for the Post-Graduate Year Two Oncology Pharmacy Residency at New York-Presbyterian Hospital.

Dr. Campbell is a member of the Hematology/Oncology Pharmacy Association (HOPA), the American Society of Health System Pharmacists (ASHP), and the New York State Counsel of Health-System Pharmacists (NYSCHP). He is a journal reviewer for the Journal of Oncology Pharmacy Practice, Annals of Pharmacotherapy, and Pharmacotherapy. Dr. Campbell has a strong interest in clinical care and education, and he is continuously seeking research and learning opportunities. His areas of clinical research focus on thrombosis in oncology patients, and the treatment of invasive fungal infections in neutropenic patients.

Accreditation

MediCom CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-033-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom NURSING CREDIT
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-033-146

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Julie Vose received honoraria related to formal advisory activities from AstraZeneca, and Pharmacyclics LLC, as well as consulting fees from AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Pharmacyclics, and MorphoSys. She has received grant support related to research activities from AstraZeneca, Bristol-Myers Squibb, and Loxo Oncology.

Dr. Jeremy Stone has disclosed no relevant financial relationships.

Dr. Nicole Lamanna has received honoraria related to formal advisory activities from AbbVie Inc., AstraZeneca, BeiGene, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech - A Member of the Roche Group, Janssen Pharmaceuticals, Inc., and Pharmacyclics, Inc. She has received grant support related to research activities from AbbVie, AstraZeneca, BeiGene, Genentech, Loxo Oncology, MingSight Pharmaceuticals, Inc., Octapharma USA, Inc., Oncternal Therapeutics, TG Therapeutics, Inc., and Verastem, Inc.

Dr. Peter Campbell has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Scott J. Hershman, MD, FACEHP, CHCP, Educational Program Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.

©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.